# Protocol for a Feasibility Study of a Cohort Embedded Randomised Controlled Trial comparing NEphron Sparing Treatment (NEST) for Small Renal Masses

Neves JB<sup>1,2</sup>, Flight J<sup>2</sup>, Cullen D<sup>2</sup>, Grant L<sup>2</sup>, Walkden M<sup>2,3</sup>, Bandula S<sup>1,3</sup>, Patki P<sup>2</sup>, Aitchison M<sup>2</sup>, Pizzo E<sup>1</sup>, Ranieri V<sup>1</sup>, Williams N<sup>1</sup>, Wildgoose WH<sup>4</sup>, Gurusamy K<sup>1</sup>, Emberton M<sup>1</sup>, Bex A<sup>1,2</sup>, Tran MGB<sup>1,2</sup> <sup>1</sup>University College London; <sup>2</sup>Royal Free London NHS Foundation Trust; <sup>3</sup>University College London Hospitals NHS Foundation Trust; <sup>4</sup>Patient representative

### **INTRODUCTION & OBJECTIVES**

Historical interventional trial recruitment difficulties demand novel study conduct approaches. We aim to assess if a novel trial design, the cohort embedded randomized controlled trial (RCT), will enable carrying out a comparison between nephron sparing treatment for small renal masses.

### METHODS

Single centre prospective cohort study with an open label embedded interventional RCT comparing percutaneous cryoablation (intervention arm) to partial nephrectomy (PN; control arm). The trial incorporates qualitative research techniques to assess barriers and recruitment improvement opportunities.

**Eligibility for RCT** Biopsy proven single renal cell carcinoma lesion, Charlson comorbidity index<3, Performance status 0 or 1, Equal technical feasibility for PN and percutaneous cryoablation.

**Primary outcome** Participant recruitment.

**Secondary outcomes** Participant trial retention, health-related quality of life, treatment complications, blood transfusion rate, Intensive Care Unit admission and renal replacement requirement rates, length of hospital stay, time to return to pre-treatment activities, number of work days lost, and health technologies costs.

Ethics UK HRA REC 19/EM/0004 **Trial registration** ISRCTN18156881

This poster presents independent research funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-0817-20013). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.



National Institute for Health Research



## **Funding** National Institute for Health Research (NIHR), Facing up 2 Kidney Cancer, Kidney Cancer UK





